Table 2.
Model-based prediction of GMCs following 2vHPV vaccination.
| Type | Initial GMC (LU/mL) | Plateau GMC (LU/mL) | 50% of initial GMC w.r.t. plateau (years) | 25% of initial GMC w.r.t. plateau (years) | GMC ratio sexual debut |
|---|---|---|---|---|---|
| HPV16 | 6606.4 (5439.0-8029.7) | 481.9 (338.5-677.7) | 1.7 (1.2-2.3) | 4.2 (2.8-6.6) | 1.0 (0.9-1.2) |
| HPV18 | 6000.0 (4792.8-7493.2 | 158.6 (100.8-235.0) | 1.8 (1.4-2.4) | 4.5 (3.3-6.3) | 1.1 (0.9-1.3) |
| HPV31 | 162.9 (122.1-215.3) | 16.6 (12.1-22.7) | 0.4 (0.4-0.5) | 0.8 (0.7-1.0) | 1.4 (1.2-1.6) |
| HPV33 | 43.7 (33.6-58.0) | 7.3 (5.0-10.2) | 0.5 (0.4-0.7) | 1.0 (0.7-1.4) | 1.5 (1.3-1.8) |
| HPV45 | 239.4 (173.4-327.4) | 24.5 (15.8-36.7) | 0.7 (0.5-1.1) | 1.6 (1.1-2.5) | 1.2 (0.9-1.4) |
| HPV52 | 94.3 (71.3-124.6) | 9.7 (6.8-13.5) | 0.5 (0.3-0.8) | 1.0 (0.6-1.7) | 1.4 (1.2-1.7) |
| HPV58 | 142.3 (107.5-187.6) | 11.8 (8.2-16.8) | 0.6 (0.5-0.8) | 1.3 (1.0-1.7) | 1.4 (1.2-1.8) |
GMC, geometric mean concentration; LU, Luminex units; w.r.t: with respect to.
GMCs predicted from the power law model, using antibody data measured up to 7.5 years after the second dose of vaccination among girls (birth cohort 2001).